Developing cancer therapeutics targeting the tumor microenvironment
Threshold (NASDAQ: THLD) is developing targeted cancer therapeutics based on the hypoxic conditions commonly found in the tumor microenvironment. Threshold's lead drug, evofosfamide, is a prodrug activated only under hypoxic conditions, and is in late-stage clinical studies for pancreatic cancer and soft tissue sarcoma.
